Acknowledgement
Supported by : Shiraz University of Medical Sciences
References
- Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-73. https://doi.org/10.1016/S0167-5699(99)01520-0
- Corm S, Berthon C, Imbenotte M, et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res 2009;33:490-4. https://doi.org/10.1016/j.leukres.2008.06.014
- Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-68. https://doi.org/10.1084/jem.20020121
- Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867-70. https://doi.org/10.1126/science.1073514
- Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21. https://doi.org/10.1182/blood-2003-11-3909
- Godin-Ethier J, Pelletier S, Hanafi LA, et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 2009;183:7752-60. https://doi.org/10.4049/jimmunol.0901004
- Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030-9. https://doi.org/10.1158/1078-0432.CCR-04-2671
- Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555-61. https://doi.org/10.1038/sj.bjc.6603477
- Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51. https://doi.org/10.1158/1078-0432.CCR-05-1966
- Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer 2013;1:13. https://doi.org/10.1186/2051-1426-1-13
- Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol 2016;103:62-77. https://doi.org/10.1016/j.critrevonc.2016.04.020
- Curti A, Aluigi M, Pandolfi S, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007;21:353-5. https://doi.org/10.1038/sj.leu.2404485
- Fukuno K, Hara T, Tsurumi H, et al. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediaterisk cytogenetics. Leuk Lymphoma 2015;56:1398-405. https://doi.org/10.3109/10428194.2014.953150
- Chamuleau ME, van de Loosdrecht AA, Hess CJ, et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008;93:1894-8. https://doi.org/10.3324/haematol.13112
- Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J Clin Invest 2007;117:1147-54. https://doi.org/10.1172/JCI31178
- Lin TL, Smith BD. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. Am J Med Sci 2011;341:404-8. https://doi.org/10.1097/MAJ.0b013e318201109d
- Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-48. https://doi.org/10.1182/blood-2006-06-001149
- Wang M, Yang C, Zhang L, Schaar DG. Molecular mutations and their cooccurrences in cytogenetically normal acute myeloid leukemia. Stem Cells Int 2017;2017:6962379.
- Mitelman F. ISCN 1995: An International System for Human Cytogenomic Nomenclature (2016). Basel, Switzerland: S. Karger, 1995.
- Folgiero V, Goffredo BM, Filippini P, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 2014;5:2052-64.
- El Kholy NM, Sallam MM, Ahmed MB, et al. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med Oncol 2011;28:270-8. https://doi.org/10.1007/s12032-010-9459-6
- Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007;109:2871-7. https://doi.org/10.1182/blood-2006-07-036863
- Curti A, Trabanelli S, Onofri C, et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 2010;95:2022-30. https://doi.org/10.3324/haematol.2010.025924
- Wang XF, Wang HS, Wang H, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol 2014;289:42-8. https://doi.org/10.1016/j.cellimm.2014.02.005
- Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014;3:e957994. https://doi.org/10.4161/21624011.2014.957994
- Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 2015;3:51. https://doi.org/10.1186/s40425-015-0094-9
Cited by
- A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy vol.10, pp.None, 2018, https://doi.org/10.3389/fonc.2020.00262
- Checkpoint inhibitors in AML: are we there yet? vol.188, pp.1, 2020, https://doi.org/10.1111/bjh.16358
- Alterations of T-cell-mediated immunity in acute myeloid leukemia vol.39, pp.18, 2020, https://doi.org/10.1038/s41388-020-1239-y
- Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review vol.27, pp.28, 2020, https://doi.org/10.2174/0929867326666191004164041
- Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review vol.12, pp.None, 2018, https://doi.org/10.3389/fimmu.2021.651687
- Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes vol.11, pp.None, 2021, https://doi.org/10.3389/fonc.2021.624742
- Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies vol.11, pp.None, 2018, https://doi.org/10.3389/fonc.2021.674720
- Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias vol.13, pp.6, 2018, https://doi.org/10.3390/cancers13061203
- Redirecting the Immune Microenvironment in Acute Myeloid Leukemia vol.13, pp.6, 2018, https://doi.org/10.3390/cancers13061423
- The guanidine thiocyanate‐high EDTA method for total microbial RNA extraction from severely heavy metal‐contaminated soils vol.14, pp.2, 2018, https://doi.org/10.1111/1751-7915.13615
- Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor vol.207, pp.6, 2018, https://doi.org/10.4049/jimmunol.2100023